Vyvgart (efgartigimod alfa-fcab) is a prescription drug that’s used to treat myasthenia gravis (MG). Vyvgart comes as a liquid solution that’s given as an intravenous (IV) infusion.

Among 47 patients with any of several forms of idiopathic inflammatory myositis (IIM) who took efgartigimod (Vyvgart Hytrulo) ...

In a case study of its so-called “drug of the year,” Trinity noted that argenx was able to successfully secure market-leader status for Vyvgart soon after its launch thanks to its “safer ...

75% of gMG patients on Vyvgart showed sustained MG-ADL improvements over 126 weeks. Vyvgart Hytrulo improved functional and QoL scores in gMG and CIDP with no rise in infections over nine ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

The Food and Drug Administration (FDA) has approved a prefilled syringe formulation of Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

WEDNESDAY, April 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the ...

The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...